ナルコレプシー治療薬の世界市場 (2022-2032年)：治療薬・適応症・製品・国別

世界のナルコレプシー治療薬の市場規模は2021年の9億1,520万米ドルから、予測期間中は15.93%のCAGRで推移し、2032年には49億1,230万米ドルの規模に成長すると予測されています。

利用可能な治療法に対する満足度の低さ、堅調なパイプライン製品、ナルコレプシー啓発プログラムの取り込みの増加、診断の改善などの要因が同市場の成長を推進しています。地域別では、米国が2021年に93.48%のシェアを示しており、2021年の8億5,550万米ドルから、予測期間中は15.24%のCAGRで推移し、2032年には43億2,770万米ドルの規模に成長すると予測されています。

当レポートでは、世界のナルコレプシー治療薬の市場を調査し、市場概要、市場成長への各種影響因子の分析、法規制・償還環境、パイプラインの分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、市場シェア、主要企業のプロファイルなどをまとめています。

第1章 市場

第2章 市場範囲

第3章 調査手法

第4章 市場概要

• ナルコレプシーの疫学
• ナルコレプシーの主な治療クラス
• 承認済み薬と研究中の治療薬
• 現在の市場規模・成長の可能性

第5章 産業考察

• 概要
• ナルコレプシーの治療ガイドライン
• 法的要件・枠組み
• 償還シナリオ

第6章 市場力学

• 概要
• 影響分析
• 市場促進要因
• 市場抑制要因
• 市場機会

第7章 競合考察

• 企業戦略
• 事業戦略

第8章 世界のナルコレプシー治療薬市場：製品別

• 概要
• 上市済み製品
  • Xywav
  • Sunosi
  • Wakix
• パイプライン製品
  • フェーズ1
  • フェーズ2
  • フェーズ3

第9章 世界のナルコレプシー治療薬市場：適応別

• 概要
• 1型ナルコレプシー
• 2型ナルコレプシー
• 2次性ナルコレプシー

第10章 世界のナルコレプシー治療薬市場：治療薬別

• 概要
• 中枢神経刺激薬
• ノルエピネフリン再取り込み阻害剤
• ヒスタミン-3(H3)受容体アンタゴニスト/インバースアゴニスト

第11章 世界のナルコレプシー治療薬市場：国別

• 概要
• 米国
• 英国
• ドイツ
• フランス
• イタリア
• スペイン
• 日本

第12章 市場：競合ベンチマーキング・企業プロファイル

• 概要
• Jazz Pharmaceuticals PLC
• Harmony Bioscience, LLC
• Axsome Therapeutics, Inc.
• Avadel Pharmaceuticals PLC
• Takeda Pharmaceutical Co Ltd
• Sumitomo Pharma Co Ltd
• Suven Life Sciences Limited
• NLS Pharmaceutics AG
• Balance Therapeutics

List of Figures

• Figure 1: Global Narcolepsy Therapeutics Market Dynamics
• Figure 2: Global Narcolepsy Therapeutics Market (by Indication), $Million, 2021 and 2032
• Figure 3: Global Narcolepsy Therapeutics Market (by Therapeutics), $Million, 2021 and 2032
• Figure 4: Global Narcolepsy Therapeutics Market (by Country), $Million, 2021-2032
• Figure 5: Global Narcolepsy Therapeutics Market Segmentation
• Figure 6: Global Narcolepsy Therapeutics Market Research Methodology
• Figure 7: Primary Research Methodology
• Figure 8: Epidemiology-Based Market Sizing and Forecasting Methodology
• Figure 9: Symptoms of Narcolepsy
• Figure 10: Impact of Narcolepsy on Day-to-Day Activities
• Figure 11: Prevalence, Diagnosed Population, and Diagnosed and Treated Population of Narcolepsy in the U.S., 2021-2032
• Figure 12: Estimated Population of Narcolepsy in EU-4 and U.K., 2021
• Figure 13: Existing Treatment Options for Managing Excessive Daytime Sleepiness (EDS) and Cataplexy in Type 1 Narcolepsy
• Figure 14: Global Narcolepsy Therapeutics Market, $Million, 2021-2032
• Figure 15: U.S. Narcolepsy Treatment Guideline
• Figure 16: European Narcolepsy Treatment Guideline
• Figure 17: Clinical Trial Authorization for Narcolepsy Therapeutics in the U.S.
• Figure 18: Steps for Obtaining Marketing Authorization
• Figure 19: U.S. FDA Review Timeline
• Figure 20: EMA Review Timeline
• Figure 21: Market Dynamics
• Figure 22: Impact Analysis
• Figure 23: Narcolepsy Patients: Undiagnosed, Diagnosed and Treated, Diagnosed and Untreated
• Figure 24: Neuroscience Research Funding (2013-2022)
• Figure 25: Recently Approved Narcolepsy Products
• Figure 26: Narcolepsy Therapeutics Unmet Needs: Patients and HCPs' Perspective
• Figure 27: Market Restraints: Delayed Diagnosis
• Figure 28: Advanced Narcolepsy Therapies
• Figure 29: Share of Key Developments and Strategies, January 2019-May 2022
• Figure 30: Synergistic Activities Share (by Company), January 2019-May 2022
• Figure 31: Funding and Business Expansion Activities (by Company), January 2019-May 2022
• Figure 32: Regulatory and Legal Developments (by Company), January 2019-May 2022
• Figure 33: Regulatory and Legal Developments (by Company), January 2019-May 2022
• Figure 34: Current Narcolepsy Treatment
• Figure 35: Share of Global Narcolepsy Therapeutics Market (by Product), $Million, 2021 and 2032
• Figure 36: Global Narcolepsy Therapeutics Market (by Commercialized Product)
• Figure 37: Xywav Concept to Launch
• Figure 38: Xywav U.S. Prescribing Information
• Figure 39: Xywav Adoption and Awareness in the U.S.
• Figure 40: Global Narcolepsy Therapeutics Market (Xywav), $Million, 2021-2032
• Figure 41: Xywav Recent Development Key Takeaways
• Figure 42: Sunosi Development and Launch Timeline in the U.S.
• Figure 43: Sunosi's Strong Market Access Position
• Figure 44: Global Narcolepsy Therapeutics Market (Sunosi), $Million, 2021-2032
• Figure 45: Wakix Development Timeline
• Figure 46: Wakix Favorable Benefit Profile Key Features
• Figure 47: Healthcare Professional and Patient Research Key Findings, 2021
• Figure 48: Global Narcolepsy Therapeutics Market (Wakix), $Million, 2021-2032
• Figure 49: Global Narcolepsy Therapeutics Market (by Pipeline Product)
• Figure 50: Recent Developments and Key Milestones in TAK-925 and TAK-861 Phase 1 Trial
• Figure 51: Global Narcolepsy Therapeutics Market (SUVN-G3031), $Million, 2021-2032
• Figure 52: Quilience's Distinctive Competitive Advantages
• Figure 53: Global Narcolepsy Therapeutics Market (SUVN-G3031), $Million, 2021-2032
• Figure 54: Global Narcolepsy Therapeutics Market (AXS-12), $Million, 2021-2032
• Figure 55: FT218 Regulatory Timeline in U.S.
• Figure 56: Global Narcolepsy Therapeutics Market (FT218), $Million, 2021-2032
• Figure 57: Global Narcolepsy Therapeutics Market (by Indication)
• Figure 58: Share of Global Narcolepsy Therapeutics Market (by Indication), $Million, 2021 and 2032
• Figure 59: Global Narcolepsy Therapeutics Market (Type 1 Narcolepsy), $Million, 2021-2032
• Figure 60: Global Narcolepsy Therapeutics Market (Type 2 Narcolepsy), $Million, 2021-2032
• Figure 61: Global Narcolepsy Therapeutics Market (Secondary Narcolepsy), $Million, 2021-2032
• Figure 62: Global Narcolepsy Therapeutics Market (by Therapeutics), $Million, 2021 and 2032
• Figure 63: Global Narcolepsy Therapeutics Market (Central Nervous System Stimulant), $Million, 2021-2032
• Figure 64: Global Narcolepsy Therapeutics Market (Norepinephrine Reuptake Inhibitor), $Million, 2021-2032
• Figure 65: Global Narcolepsy Therapeutics Market (Histamine-3 (H3) Receptor Antagonist/Inverse Agonist), $Million, 2021-2032
• Figure 66: Global Narcolepsy Therapeutics Market (by Country), $Million, 2021-2032
• Figure 67: Market Dynamics of U.S. Narcolepsy Therapeutics Market
• Figure 68: U.S. Narcolepsy Therapeutics Market, $Million, 2021-2032
• Figure 69: Market Dynamics of U.K. Narcolepsy Therapeutics Market
• Figure 70: U.K. Narcolepsy Therapeutics Market, $Million, 2021-2032
• Figure 71: Market Dynamics of Germany Narcolepsy Therapeutics Market
• Figure 72: Germany Narcolepsy Therapeutics Market, $Million, 2021-2032
• Figure 73: Market Dynamics of France Narcolepsy Therapeutics Market
• Figure 74: France Narcolepsy Therapeutics Market, $Million, 2021-2032
• Figure 75: Market Dynamics of Italy Narcolepsy Therapeutics Market
• Figure 76: Italy Narcolepsy Therapeutics Market, $Million, 2021-2032
• Figure 77: Market Dynamics of Spain Narcolepsy Therapeutics Market
• Figure 78: Spain Narcolepsy Therapeutics Market, $Million, 2021-2032
• Figure 79: Market Dynamics of Japan Narcolepsy Therapeutics Market
• Figure 80: Japan Narcolepsy Therapeutics Market, $Million, 2021-2032
• Figure 81: Total Number of Companies Profiled
• Figure 82: Jazz Pharmaceutical PLC: Product Portfolio
• Figure 83: Jazz Pharmaceuticals PLC: Overall Financials, 2019-2021
• Figure 84: Jazz Pharmaceuticals PLC: Revenue (by Business Segment), 2019-2021
• Figure 85: Jazz Pharmaceuticals PLC: Revenue (by Region), 2019-2021
• Figure 86: Jazz Pharmaceutical PLC: R&D Expenditure, 2019-2021
• Figure 87: Harmony Biosciences, LLC.: Product Portfolio
• Figure 88: Harmony Biosciences, LLC: Overall Financials, 2019-2021
• Figure 89: Harmony Biosciences, LLC: R&D Expenditure, 2019-2021
• Figure 90: Axsome Therapeutics, Inc.: Pipeline Product
• Figure 91: Axsome Therapeutics, Inc.: R&D Expenditure, 2019-2021
• Figure 92: Axsome Therapeutics, Inc.: R&D Expenditure (AXS-12), 2019-2021
• Figure 93: Regulatory Timeline of FT218
• Figure 94: Avadel Pharmaceuticals PLC: Product Portfolio
• Figure 95: Avadel Pharmaceuticals PLC: Overall Financials, 2019-2021
• Figure 96: Avadel Pharmaceuticals PLC: R&D Expenditure, 2019-2021
• Figure 97: Takeda Pharmaceutical Co Ltd: Product Portfolio
• Figure 98: Takeda Pharmaceutical Co Ltd: Overall Financials, 2019-2021
• Figure 99: Takeda Pharmaceutical Co Ltd: Revenue (by Business Segment), 2019-2021
• Figure 100: Takeda Pharmaceutical Co Ltd: Revenue (by Region), 2019-2021
• Figure 101: Takeda Pharmaceutical Co Ltd: R&D Expenditure, 2019-2021
• Figure 102: Sumitomo Pharma Co Ltd: Product Portfolio
• Figure 103: Sumitomo Pharma Co Ltd: Overall Financials, 2019-2021
• Figure 104: Sumitomo Pharma Co Ltd: Revenue (by Business Segment), 2019-2021
• Figure 105: Sumitomo Pharma Co Ltd: Revenue (by Region), 2019-2021
• Figure 106: Sumitomo Pharma Co Ltd: R&D Expenditure, 2019-2021
• Figure 107: Suven Life Sciences Limited: Product Portfolio
• Figure 108: Suven Life Sciences Limited: Overall Financials, 2019-2021
• Figure 109: Suven Life Sciences Limited: R&D Expenditure, 2019-2021
• Figure 110: NLS Pharmaceutics AG: Product Portfolio
• Figure 111: NLS Pharmaceutics AG: R&D Expenditure, 2019-2021
• Figure 112: Balance Therapeutics: Product Portfolio

List of Tables

• Table 1: Recently Marketed and Pipeline Therapies for the Treatment of Narcolepsy
• Table 2: Market Status of Commercialized and Pipeline Therapies
• Table 3: Current Therapies Available for the Treatment of Narcolepsy
• Table 4: Investigational Therapies for the Treatment of Narcolepsy
• Table 5: Narcolepsy Therapeutics Coverage
• Table 6: Narcolepsy Treatment Recommendation by American Academy of Sleep Medicine clinical
• Table 7: Most Common Symptoms in Narcolepsy
• Table 8: Key Marketed and Pipeline Central Nervous System Stimulants
• Table 9: Key Marketed and Pipeline Norepinephrine Reuptake Inhibitors
• Table 10: Key Marketed and Pipeline Histamine-3 (H3) Receptor Antagonist/Inverse Agonist
• Table 11: Key Marketed and Pipeline Products in the U.S.
• Table 12: Key Marketed and Pipeline Products in the U.K.
• Table 13: Key Marketed and Pipeline Products in Germany
• Table 14: Key Marketed and Pipeline Products in France
• Table 15: Key Marketed and Pipeline Products in Italy
• Table 16: Key Marketed and Pipeline Products in Spain
• Table 17: Jazz Pharmaceutical PLC: Key Competitors
• Table 18: Harmony Biosciences, LLC: Key Competitors
• Table 19: Axsome Therapeutics, Inc.: Key Competitors
• Table 20: Avadel Pharmaceuticals PLC: Key Competitors
• Table 21: Takeda Pharmaceutical Co Ltd: Key Competitors
• Table 22: Sumitomo Pharma Co Ltd: Key Competitors
• Table 23: Suven Life Sciences Limited: Key Competitors
• Table 24: NLS Pharmaceutics AG: Key Competitors
• Table 25: Balance Therapeutics: Key Competitors

“Global Narcolepsy Therapeutics Market to Reach $4,912.3 Million by 2032.”

Global Narcolepsy Therapeutics Market: Industry Overview

The global narcolepsy therapeutics market is projected to reach $4,912.3 million by 2032 from $915.2 million in 2021 at a CAGR of 15.93% during the forecast period 2022-2032. This The market is driven by certain factors, such as low satisfaction with available therapies, robust pipeline products, rising uptake of narcolepsy awareness programs, and improving diagnosis.

Market Lifecycle Stage

The global narcolepsy therapeutics market is in the rapidly evolving and dynamic stage, which opens ample opportunities for life science companies. Also, companies that are already in the development phase for narcolepsy therapies are trying to bring advanced treatment options to the market to improve the quality of life of people with narcolepsy. The companies operating in the global narcolepsy therapeutics market are now focusing more on disease-specific and personalized treatment options. Also, major players such as Jazz Pharmaceuticals PLC, Takeda Pharmaceuticals Co. Ltd, and Bioproject Pharma are investing heavily in research and development for their respective therapeutic products.

Impact

Albeit narcolepsy is an orphan disorder with only about 3 million people globally, the existing management of narcolepsy propounds the area as investigational for drug research and development. Currently, all available therapies are symptom-centric and do not cure the condition. In about 50% of people, disorder onset often occurs prior to age 25 with a delayed diagnosis, especially in adolescents. Insubstantial abilities of existing therapies to cover a complete range of symptoms and insignificant improvement in the quality of life of people with narcolepsy have led to the emergence of several innovative therapies in recent years. The market witnessed approximately 39 regulatory and legal developments during the time period between January 2019 and May 2022.

In addition, the disorder profoundly increases the psychosocial burden on people with narcolepsy. Associated high treatment costs and dwindled work productivity with reduced income levels are some of the key factors adding to the psychosocial burden for people living with narcolepsy. Most companies are focusing on expanding their product portfolio with the launch of best-in-class distinctive novel therapeutics and trying to address the limitations and challenges with available therapies in an effort to increase their global footprint alongside.

Market Segmentation

Segmentation 1: by Indication

• Type 1 Narcolepsy
• Type 2 Narcolepsy
• Secondary Narcolepsy

Due to recent research and development in type 1 narcolepsy, significant therapies with novel mechanisms of action, reduced dosing, and better efficacy are emerging. Therefore, the segment is dominated by type 1 narcolepsy, which held a share of 69.60% in 2021.

Segmentation 2: by Product

• Commercialized Products
• Pipeline Products

In 2021, the global narcolepsy therapeutics market (by product) is dominated by commercialized products with 100% market share.

Segmentation 3: by Therapeutic Type

• Central Nervous System Stimulant

• Norepinephrine Reuptake Inhibitor

• Histamine-3 (H3) Receptor Antagonist/Inverse Agonist

The global narcolepsy therapeutics market (by therapeutics) is presently dominated by central nervous system stimulant, with a value of $535.3 million, as of 2021.

Segmentation 4: by Country

• U.S.
• Germany
• Italy
• France
• U.K.
• Spain
• Japan

In 2021, the U.S. accounted for a share of 93.48% of the global narcolepsy therapeutics market. The segment is expected to reach $4,327.7 million in 2032 from $855.5 million in 2021 at a CAGR of 15.24% during the forecast period 2022-2032.

Recent Developments in the Global Narcolepsy Therapeutics Market

• On March 28, 2022, Jazz Pharmaceuticals PLC divested Sunosi. Axsome Therapeutics, Inc. will expand its presence in neuroscience by acquiring Sunosi (solriamfetol) from Jazz Pharmaceuticals PLC.

• On August 31, 2021, Health Canada approved Jazz Pharmaceutical's Sunosi (solriamfetol) for excessive daytime sleepiness associated with narcolepsy.

• On August 10, 2021, Harmony Biosciences LLC's successful track record of Wakix motivated Blackstone to enter a strategic financing collaboration, where the company agreed to invest up to $330.0 million of financing and growth capital in Harmony Biosciences LLC.

• On September 16, 2021, Axsome Therapeutics, Inc. announced the enrolment of the first patient in the new phase 3 clinical trial SYMPHONY (a study evaluating a mechanistic approach to treating narcolepsy) of AXS-12 in narcoleptic patients.

Demand - Drivers and Limitations

Following are the demand drivers for the global narcolepsy therapeutics market:

• Large Population of Undiagnosed and Untreated Narcolepsy Population

• Increasing Research Funding for Neuroscience

• Approval of Advanced Therapies with Novel Mechanism of Action (MoA)

• Existing Unmet Needs of Patients and Healthcare Professionals (HCPs)

The market is expected to face some limitations due to the following challenges:

• Delayed Diagnosis
• Lack of Awareness

How can this report add value to an organization?

• Innovation Strategy: The therapeutic segment helps the reader understand the different drug classes being targeted to develop novel and advanced therapies for narcolepsy in the market.

• Growth/Marketing Strategy: The global narcolepsy therapeutics market has seen major development by key players operating in the market, such as regulatory and legal developments, clinical developments, synergistic activities, product approvals, product launches and updates, mergers and acquisitions, business expansion and funding, and other developments. The favored strategy for the companies has been regulatory and legal activities along with product approvals to strengthen their position in the market.

• Competitive Strategy: Key players in the global narcolepsy therapeutics market have been analyzed and profiled in the study. Moreover, a detailed competitive benchmarking of players operating in the global narcolepsy therapeutics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

Jazz Pharmaceuticals PLC Harmony Bioscience, LLC Axsome Therapeutics, Inc. Avadel Pharmaceuticals PLC Takeda Pharmaceutical Co Ltd

Sumitomo Pharma Co Ltd Suven Life Sciences Limited NLS Pharmaceutics AG Balance Therapeutics

Table of Contents

1 Market

• 1.1 Product Definition
• 1.2 Inclusion and Exclusion

2 Market Scope

• 2.1 Key Questions Answered in the Report

3 Research Methodology

• 3.1 Data Sources
  • 3.1.1 Primary Data Source
  • 3.1.2 Secondary Data Sources
• 3.2 Market Estimation Model
• 3.3 Criteria for Company Profiling

4 Market Overview

• 4.1 Introduction
• 4.2 Epidemiology of Narcolepsy
  • 4.2.1 U.S.
  • 4.2.2 EU4 and U.K.
  • 4.2.3 Japan
• 4.3 Key Therapeutic Classes for Narcolepsy
  • 4.3.1 Central Nervous System Stimulants
  • 4.3.2 Histamine-3 (H3) Receptor Antagonist/Inverse Agonist
  • 4.3.3 Dopamine and Norepinephrine Reuptake Inhibitor (DNRI)
• 4.4 Currently Approved and Investigational Treatments for Narcolepsy
• 4.5 Current Market Size and Growth Potential, $Million, 2021-2031

5 Industry Insights

• 5.1 Overview
• 5.2 Treatment Guideline for Narcolepsy Therapeutics
• 5.3 Legal Requirements and Frameworks
  • 5.3.1 Legal Requirement and Framework in the U.S.
    • 5.3.1.1 Clinical Trial Authorization
    • 5.3.1.2 Marketing Authorization
    • 5.3.1.3 USFDA Guidelines for NDA Submission
    • 5.3.1.4 Post Authorization Regulations
  • 5.3.2 Legal Requirement and Framework in Europe
    • 5.3.2.1 EMA Drug Licence Application Process
    • 5.3.2.2 Centralized Procedure
    • 5.3.2.3 Decentralized Procedure
    • 5.3.2.4 Mutual-Recognition Procedure
    • 5.3.2.5 National Procedure
  • 5.3.3 Legal Requirements and Frameworks in Japan
• 5.4 Reimbursement Scenario

6 Market Dynamics

• 6.1 Overview
• 6.2 Impact Analysis
• 6.3 Market Drivers
  • 6.3.1 Large Population of Undiagnosed and Untreated Narcolepsy Patients
  • 6.3.2 Increasing Research Funding for Neuroscience
  • 6.3.3 Approval of Advanced Therapies with Novel Mechanism of Action (MoA)
  • 6.3.4 Existing Unmet Needs of Patients and Healthcare Professionals (HCPs)
• 6.4 Market Restraints
  • 6.4.1 Delayed Diagnosis
  • 6.4.2 Lack of Awareness
• 6.5 Market Opportunities
  • 6.5.1 Growing Opportunities in Asian Countries
  • 6.5.2 Opportunity for Narcolepsy Therapies with Novel Composition and Route of Administration

7 Competitive Insights

• 7.1 Corporate Strategies
  • 7.1.1 Synergistic Activities
  • 7.1.2 Mergers and Acquisitions
  • 7.1.3 Funding and Business Expansion Activities
• 7.2 Business Strategies
  • 7.2.1 Regulatory and Legal Developments
  • 7.2.2 Clinical Developments

8 Global Narcolepsy Therapeutics Market, by Product, $Million, 2021-2032

• 8.1 Overview
• 8.2 Commercialized Products
  • 8.2.1 Xywav
  • 8.2.2 Sunosi
  • 8.2.3 Wakix
• 8.3 Pipeline Products
  • 8.3.1 Phase 1
  • 8.3.2 Phase 2
    • 8.3.2.1 SUVN-G3031
    • 8.3.2.2 Quilience
  • 8.3.3 Phase 3
    • 8.3.3.1 AXS-12
    • 8.3.3.2 FT218

9 Global Narcolepsy Therapeutics Market, by Indication, $Million, 2021-2032

• 9.1 Overview
• 9.2 Type 1 Narcolepsy
• 9.3 Type 2 Narcolepsy
• 9.4 Secondary Narcolepsy

10 Global Narcolepsy Therapeutics Market, by Therapeutics, $Million, 2021-2032

• 10.1 Overview
• 10.2 Central Nervous System Stimulant
• 10.3 Norepinephrine Reuptake Inhibitor
• 10.4 Histamine-3 (H3) Receptor Antagonist/Inverse Agonist

11 Global Narcolepsy Therapeutics Market, by Country, $Million, 2021-2032

• 11.1 Overview
• 11.2 U.S.
• 11.3 U.K.
• 11.4 Germany
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan

12 Market - Competitive Benchmarking & Company Profiles

• 12.1 Overview
• 12.2 Jazz Pharmaceuticals PLC
  • 12.2.1 Company Overview
  • 12.2.2 Role of Jazz Pharmaceuticals PLC in the Global Narcolepsy Therapeutics Market
  • 12.2.3 Key Competitors
  • 12.2.4 Key Distributors
  • 12.2.5 Financials
  • 12.2.6 Corporate Strategies
  • 12.2.7 Analyst's Perspective
• 12.3 Harmony Bioscience, LLC
  • 12.3.1 Company Overview
  • 12.3.2 Role of Harmony Biosciences, LLC in the Global Narcolepsy Therapeutics Market
  • 12.3.3 Key Competitors
  • 12.3.4 Key Distributors
  • 12.3.5 Financials
  • 12.3.6 Corporate Strategies
  • 12.3.7 Analyst's Perspective
• 12.4 Axsome Therapeutics, Inc.
  • 12.4.1 Company Overview
  • 12.4.2 Role of Axsome Therapeutics, Inc. in the Global Narcolepsy Therapeutics Market
  • 12.4.3 Key Competitors
  • 12.4.4 Financials
  • 12.4.5 Corporate Strategies
  • 12.4.6 Analyst's Perspective
• 12.5 Avadel Pharmaceuticals PLC
  • 12.5.1 Company Overview
  • 12.5.2 Role of in Avadel Pharmaceuticals PLC in the Global Narcolepsy Therapeutics Market
  • 12.5.3 Key Competitors
  • 12.5.4 Key Distributors
  • 12.5.5 Financials
  • 12.5.6 Corporate Strategies
  • 12.5.7 Analyst's Perspective
• 12.6 Takeda Pharmaceutical Co Ltd
  • 12.6.1 Company Overview
  • 12.6.2 Role of Takeda Pharmaceutical Co Ltd in the Global Narcolepsy Therapeutics Market
  • 12.6.3 Key Competitors
  • 12.6.4 Key Distributors
  • 12.6.5 Financials
  • 12.6.6 Corporate Strategies
  • 12.6.7 Analyst's Perspective
• 12.7 Sumitomo Pharma Co Ltd
  • 12.7.1 Company Overview
  • 12.7.2 Role of Sumitomo Pharma Co Ltd in the Global Narcolepsy Therapeutics Market
  • 12.7.3 Key Competitors
  • 12.7.4 Key Distributors
  • 12.7.5 Financials
  • 12.7.6 Corporate Strategies
  • 12.7.7 Analyst Perspectives
• 12.8 Suven Life Sciences Limited
  • 12.8.1 Company Overview
  • 12.8.2 Role of Suven Life Sciences Limited in the Global Narcolepsy Therapeutics Market
  • 12.8.3 Key Competitors
  • 12.8.4 Financials
  • 12.8.5 Corporate Strategies
  • 12.8.6 Analyst Perspectives
• 12.9 NLS Pharmaceutics AG
  • 12.9.1 Company Overview
  • 12.9.2 Role of NLS Pharmaceutics AG in the Global Narcolepsy Therapeutics Market
  • 12.9.3 Key Competitors
  • 12.9.4 Financials
  • 12.9.5 Corporate Strategies
  • 12.9.6 Analyst's Perspective
• 12.1 Balance Therapeutics
  • 12.10.1 Company Overview
  • 12.10.2 Role of Balance Therapeutics in the Global Narcolepsy Therapeutics Market
  • 12.10.3 Key Competitors
  • 12.10.4 Corporate Strategies
  • 12.10.5 Analyst's Perspective